Zhiwei Hu, MD, PhD
College of Medicine
Res Assoc Professor
>Cancer ● Breast Cancer ● Choroidal Neovascularization ● Macular Degeneration ● Melanoma ● Lung Cancer ● Neoplasm Metastasis ● Necrosis ● Cancer, Vascular Tissue
Zhiwei Hu, MD, PhD, is a member of the OSUCCC – James Translational Therapeutics Program and the co-holder of five U.S. patents for a dual-targeting agent, Icon, and its applications.He was one of the first scientists who proposed to target both tumor cells and tumor neovasculature for the development of novel, dual neovascular- and cancer cell-targeted therapy. Icon has been tested as an immunotherapy for the treatment of cancer, macular degeneration and endometriosis in preclinical studies and a phase I clinical trial. Dr. Hu’s lab co-developed another dual-targeted therapeutic: factor VII-targeted photodynamic therapy using fVII peptides-conjugated photosensitizer verteporfin. He is collaborating with his colleagues to translate this work into clinical trials. His lab focuses on clarifying how drugs work and exploring ways to improve therapeutic efficacy. It also studies tumor angiogenesis, natural killer cells and cancer stem cells and their interaction in tumor microenvironment. Dr. Hu has co-authored dozens of articles appearing in well-respected journals such as Carcinogenesis, Journal of Immune Based Therapies, Vaccines and Antimicrobials and British Journal of Cancer. In addition, he served as editor-in-chief of Open Journal of Immunology and co-editor of Journal of Analytical & Bioanalytical Techniques. He has also traveled the world to share his research in presentations at events, including the Target Meeting’s World Drug Discovery Online Conference, the Japan Photodynamic Association and the International Conference on Biochemistry, Biophysics and Molecular Biology.